Celltrion said Feb. 26 it has completed all steps needed to ensure its business operations will not be disrupted regardless of how U.S. tariffs are ultimately settled.
In a statement posted on its website titled “Status of U.S. operations and the company’s position on tariff risk,” Celltrion outlined the start-up of its U.S. manufacturing base and its plans to respond to tariff uncertainty. The company acquired U.S. drugmaker Eli Lilly’s plant in Branchburg, New Jersey, late last year.
Celltrion said it finished a full facility inspection and preparations for full-scale operations by the end of January, and began contract manufacturing of Lilly products this month. It added that it has also begun validation procedures to produce Celltrion’s own products, and plans to build a system that links local production with its direct sales network to supply U.S.-made products to the U.S. market as soon as possible.
The company also disclosed short- and medium- to long-term measures on tariffs. In the near term, it said it will rely on a second-year supply volume already in the U.S. to hedge against tariff uncertainty. After that, it plans to supply the U.S. market with products made at the Branchburg plant to move beyond tariff issues.
Celltrion said that while the Trump administration’s tariff policy could change following a U.S. Supreme Court ruling invalidating reciprocal tariffs, it has completed a structural response system to tariff risk by establishing local production and supply capabilities.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.